Literature DB >> 12084853

Selective decrease in central nervous system serotonin turnover in children with dopa-nonresponsive dystonia.

Birgit Assmann1, Martin Köhler, Georg F Hoffmann, Simon Heales, Robert Surtees.   

Abstract

Childhood dystonia that does not respond to treatment with levodopa (dopa-nonresponsive dystonia, DND) has an unclear pathogenesis and is notoriously difficult to treat. To test the hypothesis that there may be abnormalities in serotonin turnover in DND we measured cerebrospinal fluid (CSF) concentrations of homovanillic (HVA) and 5-hydroxyindoleacetic (HIAA) acids, metabolites of dopamine and serotonin, respectively, in 18 children with dystonia not responsive to levodopa. These were combined with a reference population of 85 children with neurologic or metabolic disease known not to affect dopamine or serotonin metabolism. Because of the known natural age-related decrement in HVA and HIAA concentrations, the results were analyzed using multiple regression using age and DND as predictors of CSF HIAA and HVA concentrations. DND was a highly significant predictor of CSF HIAA concentration (p < 0.001) but not of CSF HVA concentration (p = 0.59). After fitting a regression model, the geometric mean ratio of CSF HIAA in DND compared with the reference range was 0.53 whereas that for CSF HVA was 0.95. We also analyzed CSF HIAA/HVA ratios. After fitting a regression model, we found no dependence on age, and the mean of CSF HIAA/HVA in DND was 0.28 whereas that for the reference range was 0.49 (p < 0.001). We conclude that a significant number of children with DND have reduced CNS serotonin turnover. Treatment with drugs that increase serotonin concentration in the synaptic cleft should be considered in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084853     DOI: 10.1203/00006450-200207000-00017

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  5 in total

1.  Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid.

Authors:  J J Luykx; S C Bakker; E Lentjes; M Neeleman; E Strengman; L Mentink; J DeYoung; S de Jong; J H Sul; E Eskin; K van Eijk; J van Setten; J E Buizer-Voskamp; R M Cantor; A Lu; M van Amerongen; E P A van Dongen; P Keijzers; T Kappen; P Borgdorff; P Bruins; E M Derks; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2013-01-15       Impact factor: 15.992

Review 2.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

3.  Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders.

Authors:  Elisa De Grandis; Mercedes Serrano; Belén Pérez-Dueñas; Aida Ormazábal; Raquel Montero; Edvige Veneselli; Mercè Pineda; Verónica González; Francesc Sanmartí; Carmen Fons; Anna Sans; Bru Cormand; Luis Puelles; Antonia Alonso; Jaime Campistol; Rafael Artuch; Angels García-Cazorla
Journal:  J Inherit Metab Dis       Date:  2010-09-18       Impact factor: 4.982

4.  Low CSF 5-HIAA in Myoclonus Dystonia.

Authors:  Kathryn J Peall; Joanne Ng; Marisela E Dy; Nutan Sharma; Simon Pope; Simon Heales; Jennifer R Friedman; Manju A Kurian
Journal:  Mov Disord       Date:  2017-09-26       Impact factor: 10.338

5.  Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms.

Authors:  E Zoons; J Booij; J D Speelman; Y E M Dreissen; M Smit; M A J Tijssen
Journal:  EJNMMI Res       Date:  2017-10-25       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.